卡米基希托通过神经营养因子减少β-粉样蛋白25-35诱导的轴突损伤

Takumi Nagamatsu1, Kaori Kubota2, Takuya Watanabe1

  • 1Department of Neuropharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.

PubMed
概括

日本草药kamikihito (KKT) 可能通过保护神经元免受β-粉样蛋白损伤来治疗阿尔茨海默病 (AD). KKT增强了神经营养因子信号传递,促进了轴突生长,并可能逆转AD相关的神经退行.